Introduction
One way in which p53 is thought to potentiate genomic stability, and consequently inhibit tumorigenesis, is by initiating cell cycle arrest, thus allowing repair of damaged DNA prior to DNA synthesis or segregation of the genome. In addition, the fact that p53 induction can initiate prolonged cell-cycle arrest suggests that it also provides a mechanism for permanently removing damaged, and potentially mutated cells from the dividing cell population (Di Leonardo et al., 1994) . The ability of p53 to induce arrest within the G 1 phase of the cell cycle in response to DNA damage is understood in most detail (for reviews see Ko and Prives, 1996; Levine, 1997) and is brought about by p53 stimulating transcription of the gene for the cyclin dependent kinase (Cdk) inhibitory protein p21. Elevated levels of p21 then inhibit the cyclin E/cdk2 and cyclin A/cdk2 kinases, thus preventing these kinases from promoting cell cycle progression (for review, see Ko and Prives, 1996; Levine, 1997) . In addition, p53 has been implicated in triggering cellcycle arrest within the G 2 phase of the cell cycle, and the available evidence suggests that this is achieved, at least in part, by p53 inducing the expression of the protein 14-3-3 sigma (Hermeking et al., 1997) . Another way in which p53 activation can result in the removal of damaged cells is through the triggering of apoptosis via transcriptional induction of genes that encode proapoptotic factors, such as Bax. The mechanisms by which a cell decides between the alternative fates of apoptosis or cell-cycle arrest, however, remain to be elucidated.
In order to gain a full appreciation of the biology of p53 and, in particular, to understand how it potentiates genomic stability and functions as a tumour suppressor, it is of key importance to decipher the mechanisms by which its levels and activity are regulated in response to genotoxic insult. Over the past 2 years, there have been a series of advances in this area ± most signi®cantly, the identi®cation and characterization of proteins that appear to directly regulate p53 activity following the induction of DNA damage. The aim of this review is to outline some of these exciting recent developments.
p53 levels are increased in response to DNA damage Levels of p53 rise dramatically within minutes of a cell sustaining DNA damage. This is achieved through post-translational modi®cations of the p53 polypeptide, with no dramatic induction of p53 mRNA levels being evident after DNA damage (Kastan et al., 1991) . One rationale for the employment of post-translational regulatory control, rather than transcriptional regulation of the p53 gene, is that this provides a particularly rapid, sensitive,¯exible and readily-reversible mechanism for regulating p53 activity in response to a number of dierent cellular stresses. Another potential advantage of post-translational regulatory control mechanisms is that these provide opportunities for DNA damage signal ampli®cation. In this regard, it is noteworthy that work by Huang et al. (1996a) has indicated that activation of p53 and ensuing cell cycle arrest can be invoked by as little as one DNA double strand break. As discussed further below, the posttranslational modi®cations of p53 that occur in response to DNA damage result in elevated protein levels by way of dramatically increasing the half-life of the protein (Maltzman and Czyzyk, 1984; Price and Calderwood, 1993; Maki and Howley, 1997) . Nevertheless, it is clear that other mechanisms for regulating p53 protein levels in response to DNA damage exist. For example, the observation that the protein synthesis inhibitor cycloheximide is capable of blocking p53 induction and partially inhibiting G 1 arrest in response to DNA damage, provides evidence for the control of p53 mRNA translation playing a key role in the p53 induction response (Kastan et al., 1991) . In this regard, both the 5' and 3' untranslated regions of p53 mRNA have been implicated in regulating p53 mRNA translation (Mosner et al., 1995; Fu and Benchimol, 1997) .
Regulation of p53 transcriptional activation potential
Although regulation of p53 protein levels in response to DNA damage is clearly important, other control mechanisms also appear to exist. For instance, the observation that low doses of UV irradiation can induce p53-dependent transcription in the absence of a signi®cant increase in p53 protein levels, suggests that the cell has developed ways to directly regulate the ability of p53 to mediate transcriptional activation (Hupp et al., 1995) . One possible mechanism for such regulation is by modulating the ability of p53 to bind sequence-speci®cally to the promoters of its target genes. Binding of p53 to DNA is essential for its function, and this is re¯ected by the fact that the majority of germ-line mutations within p53 are clustered within the protein's sequence-speci®c DNA binding domain (Hollstein et al., 1994) . One of the ®rst indications that DNA binding by p53 might be subject to control was provided by the observation that bacterially-expressed recombinant p53 exists in a latent form that is relatively inecient at binding to p53 responsive DNA elements (Hupp et al., 1992) . However, when p53 is expressed in insect cells, although the majority of the protein exists in this latent state, a sub-population has been shown to be modi®ed in a manner that enables it to bind p53 responsive elements eciently (Hupp and Lane, 1994) . Interestingly, deletion of the C-terminal 30 amino acid residues of p53 results in activation of sequence-speci®c DNA binding (Hupp et al., 1992; Halazonetis et al., 1993) , illustrating that p53 contains a negative regulatory domain in its C-terminus, and suggesting that this domain might be subject to regulation in vivo. Consistent with this idea, induction of sequence-speci®c DNA binding by p53 can be achieved by a number of factors that impinge on this regulatory domain. For example, binding of monoclonal antibody pAb421 to the C-terminus of p53 activates sequence-speci®c DNA binding and can trigger the transcriptional activity of p53 in vivo (Hupp et al., 1992; . Furthermore, synthetic peptides derived from the p53 C-terminus can interact with the C-terminal regulatory domain and activate p53 sequence-speci®c DNA binding (Hupp et al., 1995; Jayaraman and Prives, 1995; Lee et al., 1995; Selivanova et al., 1997; Muller-Tiemman et al., 1998) . These data are consistent with a model in which allosteric modi®cations of the p53 C-terminal regulatory domain activate the sequence-speci®c DNA binding potential of the protein. Of more physiological relevance is the fact that post-translational modi®cations of amino acid residues in the p53 Cterminal region can activate p53 sequence-speci®c DNA binding. As discussed below, such regulation of p53 DNA binding potential has the capability of being modulated in response to DNA damage.
A further mechanism by which the intrinsic activity of p53 as a transcription factor could be regulated is by post-translational modi®cation of the N-terminal transcriptional activation domain. This region, which encompasses amino acid residues 1 ± 43 of the p53 polypeptide (Unger et al., 1992) , has been shown to interact in vitro with protein components of the basal transcriptional machinery, such as the TATA boxbinding protein (TBP), a number of TBP-associated factors (TAFs; for reviews see Ko and Prives, 1996; Levine, 1997) and the transcriptional co-activators CBP and p300 (see below). In support of a physiological relevance of these observations, mutation of the speci®c amino acid residues that interact with the transcriptional machinery render p53 transcriptionally inactive . The fact that the N-terminus of p53 can interact with a number of dierent proteins has lead to speculation that these interactions may be regulated in response to DNA damage.
Regulation of p53 by Mdm2
One well characterized example of a protein that interacts with the p53 N-terminus is the product of the mouse Mdm2 gene, together with its human homologue, Hdm2. Mdm2 was initially identi®ed by virtue of the fact that it is ampli®ed in the mouse tumorigenic cell line 3T3DM (Fakharzadeh et al., 1991) . Similarly, HDM2 is ampli®ed in a large proportion of human sarcomas (Oliner et al., 1992) . Subsequently, the 491 amino acid residue Mdm2 protein was demonstrated to co-purify with p53 and was shown to be capable of interacting with p53 in vitro (Momand et al., 1992) . Taken together with the fact that over-expression of Mdm2 was shown to be capable of inhibiting IR-induced p53-dependent G 1 arrest , these ®ndings strongly suggest that Mdm2 is a physiological negative modulator of p53 activity. As discussed below, various studies have now established that Mdm2 is indeed a regulator of p53, and have shown that this regulation is achieved by at least two distinct mechanisms.
Initial observations led to a model whereby Mdm2 regulates p53 by directly inhibiting the ability of p53 to function as a transcriptional activator. As mentioned above, p53 is believed to activate transcription by interacting with components of the transcriptional machinery via the N-terminus of the polypeptide (for review see Ko and Prives, 1996) . Interestingly, sequence alignments of p53 from a number of dierent species reveals a highly conserved motif in the N-terminus (conserved region I), part of which corresponds to the Mdm2 binding region. Interaction of Mdm2 with this N-terminal region of p53 has been demonstrated to inhibit the ability of p53 to activate transcription (Momand et al., 1992; Oliner et al., 1993) . Furthermore, mutational analysis of the p53 N-terminus has revealed that the amino acid residues required for p53-mediated transcriptional-activation overlap significantly with those required for interaction with Mdm2 . Thus, it is believed that Mdm2 can inhibit the function of p53 as a transcription factor by binding to the p53 N-terminus, thereby preventing p53 from interacting with the transcriptional machinery and preventing the activation of p53-responsive genes. Interestingly, the promoter of the Mdm2 gene contains a p53 binding site and is transcribed in a p53-dependent manner (Barak et al., 1993; Perry et al., 1993; Wu et al., 1993) . This has led to a model in which activation of p53 upon sustaining DNA damage leads to up-regulation of the Mdm2 protein, thus providing a negative feedback regulatory loop for p53 activity.
Recent work has indicated that Mdm2 also plays a key role in regulating p53 protein levels by modulating p53 stability. A variety of studies have revealed that p53 has an extremely short half-life in an unstressed cell, but becomes markedly more stable following DNA damage (Maltzman and Czyzyk, 1984; Price and Calderwood, 1993; Maki and Howley, 1997) . Furthermore, the instability of p53 under normal conditions has been correlated with it being eciently targeted for ubiquitin-dependent proteasome-mediated degradation (Maki et al., 1996) . Notably, several recent reports have provided data consistent with a model in which Mdm2 interacts with p53 in undamaged cells and targets it for ubiquitin-mediated degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Fuchs et al., 1998) . More speci®cally, Mdm2 is believed to translocate p53 from the nucleus of the cell into the cytoplasm, where it then undergoes degradation (Dobbelstein et al., 1998; Freedman and Levine, 1998; Tao and Levine, 1999) . These observations are of particular interest, given that DNA damage increases the levels of p53 in the nucleus (Goldman et al., 1996) , and suggest that disruption of the ability of Mdm2 to target p53 for degradation could be a mechanism to increase p53 half-life in response to DNA damage.
Recent reports have provided strong support for the above model and have indicated that disruption of p53/ Mdm2 function can be achieved by at least two mechanisms. One of these mechanisms was discovered by way of the identi®cation of an alternative reading frame (ARF) in the locus encoding the Cdk inhibitor p16. Speci®cally, work on ARF demonstrated that it can bind to Mdm2 and thus prevent Mdm2-mediated proteolytic destruction of p53 (for review, see Prives, 1998) . Nevertheless, although this regulation has been shown to occur under certain physiological conditions, the observation that ARF 7/7 cells are still capable of inducing p53 normally in response to DNA damage, suggests that ARF-dependent mechanisms are not essential for the induction of p53 levels in response to genotoxic stress (Kamijo et al., 1997) . A second mechanism for modulating the Mdm2±p53 complex initially became apparent from the studies of . In this report it was demonstrated that phosphorylation of p53 at serine-15 occurs after DNA damage and that this leads to a reduced interaction of p53 with Mdm2. Furthermore, this study revealed that phosphorylation of p53 in vitro at serine-15 inhibits the interaction between p53 and Mdm2. More recently, it has been demonstrated that mutation of serine-20 renders p53 less stable and more prone to Mdm2 mediated degradation (Unger et al., 1999) . These data, taken together with observations that p53 peptides phosphorylated at serine-20 are less ecient competitors of the p53/Mdm2 interaction than non-phosphorylated peptides (Unger et al., 1999) , suggest that phosphorylation of serine-15 and/or serine-20 in response to DNA damage might play a role in the regulation of p53 via aecting its interaction with Mdm2. These data are consistent with a model in which multiple N-terminal modi®cations of p53 in response to DNA damage inhibit the interaction of p53 with Mdm2, thus both elevating p53 levels and converting it into a form that is capable of interacting productively with the transcriptional machinery (see Figure 1 ).
Post-translational modi®cation of p53 in vitro
As mentioned above, one mechanism to rapidly and eectively regulate p53 in response to DNA damage is by post-translational modi®cation. Although recent advances have been made in our understanding of the post-translational modi®cations that occur to p53 in vivo, much of the initial studies of how p53 is covalently modi®ed and regulated came from studies in vitro. These studies have lead to the discovery of two major mechanisms of p53 modi®cation, namely phosphorylation and acetylation.
Phosphorylation
Phosphorylation of p53 in response to DNA damage is one mechanism by which its activity may be modulated. This assumption is supported by the Figure 1 Model for regulation of p53 by Mdm2. In an undamaged cell, p53 is complexed with Mdm2 and targeted for ubiquitin-dependent proteolysis. DNA damage induces phosphorylation of p53 at serine-15 and serine-20, displacing Mdm2. In addition to revealing the transactivation domain of p53, displacement of Mdm2 results in p53 no longer being eciently targeted for degradation, leading to an increase in the levels of cellular p53. Activated p53 is then capable of inducing the transcription of genes that lead to cell cycle arrest, apoptosis, or enhanced DNA repair observations that incubation of cell lines expressing p53 with the phosphatase inhibitor okadaic acid results in an increase in p53 phosphorylation state and increased levels of p53 protein (Zhang et al., 1994) . Indeed, p53 has been shown to be phosphorylated in vitro on both the N-terminal and C-terminal regulatory domains by a number of dierent kinases, including cyclin dependent kinases (Cdks) at serine-315 (Bischo et al., 1990; Price et al., 1995; Wang and Prives, 1995) , casein kinase I (CKI) at serine-6 and serine-9 (Milne et al., 1992) , casein kinase II (CKII) at serine-392 , protein kinase C (PKC) at serine-378 (Baudier et al., 1992) , mitogen-activated protein kinase (MAPK) at threonine-73 and threonine-83 of mouse p53 (Milne et al., 1994) , Jun amino-terminal kinase (JNK) at serine-34 of mouse p53 (Milne et al., 1995) , Raf kinase within the N-terminal 27 amino acid residues of p53 (Jamal and Zi, 1995) , the DNAdependent protein kinase (DNA-PK) at serine-15 and serine-37 (Lees-Miller et al., 1990; Shieh et al., 1997) in addition to the DNA-PK related kinases, ATM at serine-15, and ATR at serine-15 and serine-37 (Banin et al., 1998; Canman et al., 1998; Lakin et al., 1999; Tibbetts et al., 1999) . In support of some of these phosphorylation events being involved in regulating p53 activity, phosphorylation of the p53 C-terminal regulatory domain by CKII, PKC or Cdks has been shown to activate p53 sequence-speci®c DNA binding in vitro (Hupp et al., 1992; Hupp and Lane, 1994; Takenaka et al., 1995; Wang and Prives, 1995) . Furthermore, phosphorylation of serine-15 of p53 has been shown to inhibit the interaction of p53 with Mdm2 in vitro .
In light of the above, an attractive hypothesis is that phosphorylation of p53 at multiple sites in vivo regulates p53 function in several ways. Thus, phosphorylation at N-terminal sites could inhibit interactions with Mdm2, leading to elevated p53 levels and elevated p53 transcriptional activity, whereas phosphorylation at C-terminal sites could trigger the sequence-speci®c DNA binding potential of the protein. Such models have been tested extensively by a number of dierent laboratories through expressing recombinant p53 derivatives containing mutations in speci®c phosphorylation sites and then ascertaining the activity of the resulting proteins. Using this approach, mutation of either the DNA-PK/ATM/ATR phosphorylation site (serine-15) or the CKII site (serine-392) has been shown to impair the ability of p53 to mediate growth suppression, suggesting that these phosphorylation sites may be physiologically relevant for regulating p53 activity (Milne et al., 1992; Fiscella et al., 1993) . However, several other reports have illustrated that mutation of speci®c phosphorylation sites in p53 results in no abrogation of either p53 functional activity or up-regulation of p53 levels in response to DNA damage (for example Slingerland et al., 1993; Crook et al., 1994; Fiscella et al., 1994; Blattner et al., 1999) . One interpretation of these data is that multiple, functionally overlapping, phosphorylation events control p53 activity. However, one recent report revealed that mutation of all known phosphorylation sites in the N-terminus and C-terminus of p53 has no dramatic eect on the ability of mutant p53 to activate transcription of receptor genes nor on its ability to be stabilized in response to DNA damage (Ashcroft et al., 1999) . Although the above data provide a confused picture of the relevance of phosphorylation regulating p53 activity, certain caveats have to be introduced into the interpretation of the results. For example, variability in these experiments could be due to celltype dierences and the fact that, in many experiments, mutant p53 is being over expressed in cell lines. Moreover, it is possible that further regulatory phosphorylation sites that regulate p53 activity in vivo have yet to be identi®ed. Thus, although phosphorylation of p53 is likely to play an essential role in regulating its activity, more extensive and subtle studies are required to elucidate the precise molecular mechanisms by which this may be achieved.
Acetylation
Acetylation of lysine residues present in histones has long been implicated in the regulation of transcription. Further support for this idea has been provided by the demonstration that certain histone acetyl-transferase (HAT) enzymes correspond to key transcriptional coactivators, such as CBP/p300 and PCAF (for reviews see Grunstein, 1997; Kouzarides, 1999) . Initial speculation about a link between p53 regulation and HATs came from observations that, in addition to interacting with p53, adenovirus E1A and SV40 large T-antigen can bind to CBP/p300 (Eckner et al., 1994; 1996) . Furthermore, reports that E1A can bind to either p300/CBP or p53, interfering with the transcriptional activity of p53, has lent support to this idea (Steegenga et al., 1996; Lill et al., 1997) . More recently, these claims have been substantiated by reports that CBP/ p300 can bind to the N-terminus of p53 and aect its transcriptional activity and cell cycle regulatory functions (Avantaggiati et al., 1997; Gu et al., 1997a; Lill et al., 1997; Scolnick et al., 1997) . The mechanism by which this regulation occurs is now beginning to be elucidated. Thus, in addition to potentially playing a role in acetylating histones at p53-dependent promoters, CBP/p300 has been shown to be able to acetylate p53 at lysine-373 and lysine-382, whilst PCAF can acetylate p53 at lysine-320 (Gu and Roeder, 1997; Liu et al., 1999) . Furthermore, and consistent with the fact that these acetylation events occur within the C-terminal region of p53 implicated in regulating its DNA binding potential, acetylation of these residues has been found to activate p53 sequencespeci®c DNA binding. This may therefore explain, in part, how acetylation activates p53 transcriptional activity (Gu and Roeder, 1997; Liu et al., 1999) . Notably, phosphorylation events at serine-33 and/or serine-37 , in addition to serine-15 (Lambert et al., 1998) , have been implicated in recruiting CBP/p300 to p53 and controlling p53 acetylation status in vitro. The possibility exists, therefore, that activation of p53 by increasing its ability to bind to and activate promoters is regulated by a combination of phosphorylation and acetylation events.
Post-translational modi®cation of p53 in vivo As described above, it is evident from in vitro studies that p53 is capable of undergoing a number of covalent post-translational modi®cations. However, whether these modi®cations have direct relevance in vivo remains controversial. Although post-translational modi®cation of p53 has been known for many years, it is only relatively recently that the eects of DNA damage on these has begun to be clearly de®ned. Initially, sites on p53 phosphorylated in response to DNA damage were identi®ed by phospho-peptide mapping. For example, using this approach Milne et al. (1995) described the phosphorylation of mouse p53 at serine-34 (equivalent to serine-37 of human p53 by sequence homology) in response to UV. However, although these types of experiments have proved informative, certain caveats must be maintained with this approach. For example, labelling cellular proteins using radioactive phosphate will itself cause DNA damage and activate pathways that signal to p53. One major tool that has overcome some of these problems is the development of phospho-or acetylation-speci®c antibodies that can detect modi®cations at speci®c p53 residues. Indeed, studies using these reagents have implied that a number of the modi®cations of p53 that have been identi®ed in vitro are used to regulate p53 activity in vivo (see Figure 2 ).
Phosphorylation
One of the ®rst demonstrations that p53 is phosphorylated in vivo was provided by Wang and Eckhart (1992) who, by a phospho-peptide mapping approach, demonstrated that cellular mouse p53 is phosphorylated at serine residues 7, 9, 18 and 37. Using a similar approach, Siliciano et al. (1997) mapped IR-induced phosphorylation to two serine resides situation in the N-terminal 24 amino acid residues of human p53. Subsequently, by using phospho-speci®c antibodies, serine-15 was identi®ed as a site on p53 phosphorylated in response to DNA damage induced by UV or IR (Siliciano et al, 1997; Shieh et al., 1997) . These data, taken together with in vitro experiments addressing the importance of serine-15 phosphorylation in regard to modulating the interaction between p53 and Mdm2 (see above), provide an attractive model as to how p53 half-life and transcriptional activity may be increased in response to DNA damage. In this model, p53 is targeted for ubiquitin-mediated degradation in the undamaged cell by interacting with Mdm2. Upon DNA damage, however, p53 becomes phosphorylated on serine-15 in vivo and no longer interacts with Mdm2 eectively (Siliciano et al., 1997; Shieh et al., 1997) . The half-life of p53 is therefore prolonged due to the fact that it is no longer degraded in a Mdm2-dependent fashion. In support of this model, it was recently shown that substitution of serine-15 with glutamic acid (a residue that sometimes mimics serine phosphorylation), results in a slight stabilization of p53 in vivo (Ashcroft et al., 1999) . Furthermore, the disruption of the p53/Mdm2 complex may allow p53 to interact with transcriptional coactivators, TBP, TAFs and/or other components of the transcriptional apparatus. Finally, phosphorylation of the p53 N-terminal region could trigger modi®cations elsewhere in the protein, including acetylation in the C-terminal domain that activates sequence-speci®c DNA binding .
In addition to the above studies, two recent reports have illustrated that other phosphorylation events at the N-terminus of p53 can also aect the interaction of p53 with Mdm2. Thus, Shieh et al. (1999) have shown that in addition to serine-15, serine-20 is also phosphorylated in response to DNA damage. These observations are particularly interesting given that serine-20 resides in the region of p53 that binds to Mdm2 (Picksley et al., 1994; Kussie et al., 1996) . Consistent with this, Unger et al. (1999) found that mutation of serine-20 to alanine signi®cantly increases the negative regulation of p53 by Mdm2 and that peptides phosphorylated at serine-20 are less ecient inhibitors of the p53±Mdm2 interaction than nonphosphorylated peptides. Thus, is would appear that DNA damage induced phosphorylation of p53 at serine-20 also contributes to the regulation of p53 via its interaction with Mdm2. It is clear from these studies that a number of dierent, possibly overlapping, modi®cations of the N-terminus of p53 can regulate the interaction of Mdm2 with p53 and that further experiments are required to establish the precise mechanisms by which these modi®cations impinge on the regulation of p53 by Mdm2.
Further studies using phospho-speci®c antibodies have indicated that DNA damage also in¯uences phosphorylation events at other sites on the p53 polypeptide. Thus, both serine-33 and, to a lesser extent, serine-37 have been shown to be phosphory- Figure 2 Post-translational modi®cations of p53 in vivo. Serine residues 15, 20, 33, 37 and 392 are phosphorylated in response to DNA damage. Furthermore, serine-376 is dephosphorylated in response to IR. In addition, p53 is acetylated at lysine residues 320, 373 and 382 after DNA damage. Kinases and HATs that have been reported to modify these sites in vitro are illustrated. The only kinases that have been demonstrated to be involved in signalling DNA damage to p53 in vivo are ATM and ATR (denoted by italics) lated in response to DNA damage . Serine-33 is the major phosphorylation site in vitro for the Cdk-activated kinase (CAK; Ko et al., 1997) . CAK is a particularly attractive candidate for a kinase that can phosphorylate p53 in response to DNA damage, because it forms part of the transcription factor IIH (TFIIH) multi-protein complex, which plays key roles in transcription and in DNA nucleotide excision repair. Nevertheless, the role of CAK in the regulation of p53 in vivo, and speci®cally the idea that CAK may provide a mechanism to couple p53 phosphorylation with DNA damage, remain to be demonstrated.
Recent work has suggested that overlapping but distinct mechanisms of p53 regulation are invoked by dierent forms of DNA damage. Thus, although p53 is phosphorylated on serine-15 in response to IR or UV, the CKII site situated at serine-392 in human p53 has been shown to be phosphorylated in response to UV but not IR (Kapoor and Lozano, 1998; Lu et al., 1998; Blaydes and Hupp, 1998) . This phosphorylation event is of particular interest, because phosphorylation of this site in vitro activates sequence-speci®c DNA binding of p53. Consistent with this, Kapoor and Lozano (1998) have reported data consistent with a model in which p53 DNA binding is activated in response to UV. However, these particular experiments do not rule out the possibility that this activation could be performed by phosphorylation of p53 at other sites apart from, or in addition to, serine-392. In addition to phosphorylation of p53 occurring in response to DNA damage, Waterman et al. (1998) have provided persuasive evidence that de-phosphorylation of p53 in response to DNA damage may also regulate p53 activity. These studies revealed that, in response to IR, p53 is dephosphorylated on serine-376, a residue lying in the C-terminal regulatory region of p53. Interestingly, dephosphorylation of serine-376 induces the interaction of p53 with 14-3-3 proteins that, in turn, activate its DNA binding potential. These studies have lead to the proposition that dephosphorylation is a key regulatory mechanism for p53 in response to DNA damage.
Acetylation
One further way of activating p53 DNA binding in response to DNA damage is through acetylation. Acetylation of p53 is achieved in vitro by CBP and PCAF at lysines 320, 373 and 382, and this results in an increased anity of p53 for DNA (see above). Recently, by the use of acetylation-speci®c antibodies raised against these acetylation sites, Sakaguchi et al. (1998) have demonstrated that lysine-382 is acetylated in response to IR or UV-induced DNA damage. Furthermore, a similar study by Liu et al. (1999) recently demonstrated the acetylation of p53 at Lys-320 and Lys-373 in response to DNA damage. Additional experiments, however, are required to establish the physiological functions of these modifications in regulating p53 activity in vivo. In particular, it will be of interest to determine whether mutations of the various acetylation sites in¯uences the ability of p53 to be modulated in response to DNA damage. Furthermore, in light of the fact that prior phosphorylation of p53 on serine-33 and/or serine-37 has been shown to potentiate p53 acetylation by CBP/p300 in vitro, it will be of interest to determine the eects of mutating these phosphorylation sites on p53 acetylation status in the cell, both before and after DNA damage.
Signallers to p53
Identifying the speci®c residues modi®ed in vivo on p53 in response to DNA damage has allowed a greater understanding of the molecules that may signal to p53 in vivo. Initial studies ascertaining the kinases that signal to p53 in vivo exploited inhibitors of kinases known to phosphorylate p53 in vitro. For example, Price and Youmell (1996) found that the PI 3-kinase inhibitor wortmannin blocked induction of p53 DNA binding activity in response to actinomycin D and radiation, in addition to blocking the transcriptional activity of p53 by actinomycin D. These data suggest that members of this kinase family may signal to p53 in response to DNA damage. Indeed, a number of recent reports have implicated PI 3-kinase like family members as being instrumental in mediating phosphorylation of serine-15 and regulating p53 in response to DNA damage.
Members of the PI 3-kinase family were originally identi®ed by their ability to mediate intra-cellular signalling events by way of phosphorylating inositol lipids (for review see Toker and Cantley, 1997) . However, this family of proteins has recently been expanded by the identi®cation of a subset of these proteins that appear to function primarily, if not exclusively, as protein kinases (for reviews see Jackson, 1996; Hoekstra, 1997) . Notably, several of these proteins have been shown to be involved in the detection, signalling and/or repair of DNA damage. Members of this sub-family include the catalytic subunit of DNA-PK (DNA-PKcs), the protein encoded by the gene mutated in the genetic disorder ataxia-telangiectasia (ATM) and its relative ATR, together with the more distantly-related protein TRRAP. Recently, DNA-PK, ATM and ATR have all been implicated in being involved in regulating p53 activity in response to DNA damage. However, unlike DNA-PK, ATM and ATR, TRRAP appears to contain no intrinsic kinase activity, but instead copuri®es both in yeast and mammals with protein complexes that contain HAT activity (Grant et al., 1998; McMahon et al., 1998; Saleh et al., 1998; Vassilev et al., 1998) . No evidence has yet been published implicating a role for TRRAP in signalling DNA damage, but it is interesting to speculate that, TRRAP may be involved in the detection and signalling of DNA damage to p53 by acetylation as opposed to phosphorylation. Furthermore, the product of the gene mutated in the human genetic disorder Nijmegen breakage syndrome (NBS) has been reported to be involved in controlling p53 activation. Below, we brie¯y describe these proteins and their links with DNA damage signalling to p53.
The DNA-dependent protein kinase (DNA-PK) DNA-PK was identi®ed originally as a protein serine/ threonine kinase capable of being activated in vitro in a DNA end-dependent manner (for review see Smith and Jackson, 1999) . Puri®cation and subsequent analysis of DNA-PK by a number of laboratories revealed that DNA-PK consists of a large catalytic subunit (DNAPKcs) that is targeted to DNA ends by the Ku heterodimer, which consists of the polypeptides Ku70 and Ku80 (Dvir et al., 1993; Gottlieb and Jackson, 1993) . Binding of DNA-PK to DNA ends in vitro is required for it to phosphorylate a number of dierent substrates, including p53 (for review see Smith and Jackson, 1999) . The observations that cells defective in DNA-PK exhibit radiosensitivity, taken together with the fact that DNA-PK activity is triggered in vitro by DNA breaks, has lead to the proposal that DNA-PK may be involved in the repair of DNA double-strand breaks and in the detection and signalling of DNA damage to downstream eector molecules, such as p53.
Consistent with the above signalling model, DNA-PK has been shown to be capable of phosphorylating p53 on serine-15 and serine-37 in vitro in a DNAdependent manner (Lees-Miller et al., 1990; . Furthermore, phosphorylation of p53 by DNA-PK in vitro has been reported to disrupt the interaction of p53 with Mdm2 and alleviate Mdm2-mediated inhibition of p53 dependent transcription . These data have lead to the speculation that DNA-PK regulates p53 activity by phosphorylating serine-15 in vivo in response to DNA strand breaks and, in this way, regulates p53 stability and transcriptional activity by inhibiting its interaction with Mdm2. However, a variety of reports have revealed that p53 regulation, transcriptional activation of p21, and induction of p53-dependent cell cycle checkpoints are normal in cell lines carrying mutations in DNA-PKcs, or in mice containing a targeted disruption in the genes for Ku80 or Ku70 (Bogue et al., 1996; Fried et al., 1996; Guidos et al., 1996; Huang et al., 1996b; Jongmans et al., 1996; Nacht et al., 1996; Candeias et al., 1997; Gu et al., 1997b; Nussenzweig et al., 1996; Rathmell et al., 1997; Abraham et al., 1999) . Taken together, these data appear to rule out DNA-PK as playing a key role in regulating p53 function after DNA damage. Nevertheless, and somewhat contradictory with the above reports, Woo et al. (1998) have presented evidence that DNA-PK is crucial, although not sucient, for the upregulation of p53 DNA binding potential in response to DNA damage. However, a more recent study illustrating that the DNA-PKcs-de®cient cell line employed in the above experiments bears a mutation in the p53 DNA binding domain has cast doubts over the interpretation of these data (G Wahl, personal communication). In conclusion, despite the inherent attractions of the model that DNA-PK signals to p53 in response to DNA damage, as yet no persuasive evidence exists for this being the case.
The ataxia-telangiectasia gene product (ATM)
The human autosomal recessive disorder ataxiatelangiectasia (A-T) is characterized by a variety of debilitating symptoms. The most severe clinical manifestations of A-T are progressive cerebellar degeneration and immune de®ciencies, in addition to occulocutaneous telangiectasia, growth retardation, and certain characteristics of premature ageing. The fact that A-T patients exhibit an approximately 100-fold increased incidence of cancer, in addition to A-T cells exhibiting chromosomal instability and radiosensitivity, has led to speculation that the A-T gene product may somehow be involved in the detection and signalling of DNA damage (for review see Rotman and Shiloh, 1998) . The gene mutated in ataxia-telangiectasia patients was mapped to human chromosome 11q22-23, and the gene, termed ATM, has been cloned (Gatti et al., 1988; Savitsky et al., 1995) .
Initial clues suggesting that ATM may be involved in regulation of p53 in response to DNA damage came from observations that cell cycle checkpoint controls and up-regulation of p53 in response to IR are defective in A-T cells (Kastan et al., 1992; Khanna and Lavin, 1993; Canman et al., 1994) . Interestingly, in some instances, p53 up-regulation in A-T cells is apparent at later time points compared to controls. These data, taken together with the observations that A-T cells show normal regulation of p53 in response to UV (Khanna and Lavin, 1993; Canman et al., 1994) , suggest that other, functionally overlapping, pathways might be capable of signalling to p53 in response to dierent forms of DNA damage. Notably, the defects in regulation of p53 in response to IR in A-T cells are paralleled by defects in phosphorylation of serine-15 in A-T cells following IR exposure (Siliciano et al., 1997; Canman et al., 1998) . Thus, ATM has been proposed to act upstream of p53 in the signal transduction pathway activated in response to IR. This idea has recently received strong support by the observations that ATM mediates phosphorylation of serine-15 of p53 in vitro, and that this kinase activity is activated in response to IR, but not UV (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . Therefore, p53 stabilization in response to IR is believed to occur, at least in part, by ATM-dependent phosphorylation of p53 at serine-15, thereby disrupting the MDM2/p53 complex and increasing the half-life and transcriptional properties of p53 in a DNA damage dependent fashion (see Figure 3) . However, these data do not discount the possibility that other kinases may target serine-15 of p53 in a ATM dependent manner in vivo. In this regard, it will be of interest to establish whether kinases that act downstream of ATM in DNA damage signalling pathways such as Chk1 and Chk2 (Matsouka et al., 1998; Blasina et al., 1999; Brown et al., 1999; Chen et al., 1999) , are also capable of targeting p53.
In addition to being a key regulator of p53 protein levels in response to DNA damage, ATM has also been implicated in the activation of p53 DNA binding in response to IR. When a cell is exposed to IR, p53 is dephosphorylated on serine-376 (Waterman et al., 1998) . Notably, this has been shown to be dependent on ATM, as evidenced by the fact that serine-376 dephosphorylation in response to IR is aberrant in A-T cells (Waterman et al., 1998) . Because ATM is a protein kinase and does not appear to bear motifs characteristics of phosphatase enzymes, it seems most likely that ATM directly or indirectly in¯uences at the activity of a p53 phosphatase in response to DNA damage. Dephosphorylation of p53 at serine-376 induces the interaction of p53 with 14-3-3 proteins, resulting in activation of sequence-speci®c DNA binding. Taken together with the data on ATM targeting the p53 N-terminus, these results suggest that, in response to DNA damage, ATM-dependent signalling enhances p53 stability, activates its transcriptional potential, and stimulates its ability to bind to the promoters of its target genes (see Figure 3) .
The ATM-related polypeptide, ATR
Although ATM is required for eective phosphorylation of p53 at serine-15 in response to IR, A-T cells appear to be fully pro®cient in stabilizing p53 and phosphorylating p53 on serine-15 in response to UV and various other forms of DNA damaging agents (Khanna and Lavin, 1993; Canman et al., 1994; Siliciano et al., 1997) . In addition, although the p53 response is severely defective in A-T cells exposed to IR, in some instances the response is not completely absent, but severely delayed (Lu and Lane, 1993; Canman et al., 1994) . These two observations imply that other, functionally partially overlapping, mechanisms of signalling to p53 are present within the cell. One candidate for another kinase that could signal to p53 in response to DNA damage is the ATM-related polypeptide ATR, which is the mammalian homologue of the Schizosaccharomyces pombe cell cycle checkpoint protein Rad3p Cimprich et al., 1996) . Although it is evident that Rad3p, and its Saccharomyces cerevisiae homologue Mec1p, are essential for cell cycle checkpoint arrest following DNA damage or replication block, the lack of mammalian cell lines containing null mutations in both ATR alleles has severely hampered eorts to de®ne the physiological functions of ATR. Nevertheless, two recent papers have reported that overexpression of a kinase-inactive (kinase-dead) dominant negative form of ATR renders cells hypersensitive to a variety of DNA damaging agents, illustrating that ATR is indeed involved in the detection and signalling of DNA damage in mammalian cells (Cliby et al., 1998; Wright et al., 1998) .
Signi®cantly, ATR immunoprecipitates have been shown to contain an associated kinase activity and, similar to ATM, ATR catalytic activity has been found to mediate phosphorylation of p53 at serine-15 in vitro (Canman et al., 1998; Tibbetts et al., 1999) . Indeed, ATR was biochemically puri®ed by Lakin et al. (1999) through taking the approach of identifying and characterizing novel p53 serine-15 kinases activities present in human cell extracts. Moreover, recent studies have revealed that ATR regulates p53 activity in vivo. Thus, over-expression of dominant-negative ATR disrupts the phosphorylation of p53 at serine-15 in response to certain forms of DNA damage (Tibbetts et al., 1999) . Over-expression of kinase-dead ATR has also been shown to completely abrogate serine-15 phosphorylation and up-regulation of p53 levels in response to UV, implicating ATR in the detection and signalling of DNA damage induced by this agent (Tibbetts et al., 1999) . Furthermore, when cells expressing dominant-negative kinase inactive ATR were exposed to IR, although an initial up-regulation of p53 levels was apparent, the prolonged upregulation and phosphorylation of p53 at serine-15 was found to be defective. These observations are of Figure 3 Model for post-translational modi®cation of p53 in response to DNA damage in vivo. In an undamaged cell, p53 is targeted for ubiquitin-mediated degradation via its interaction with Mdm2. Serine-15 of p53 is phosphorylated in an ATM/ATRdependent manner in response to IR, and an ATR-dependent manner in response to UV. Furthermore, in response to IR, serine-376 is de-phosphorylated in an ATM-dependent manner, resulting in activation of p53 DNA binding via interaction with 14-3-3 proteins. It remains to be established whether similar de-phosphorylation of serine-376 occurs in response to other forms of DNA damage such as UV. Further phosphorylation events, by as yet unidenti®ed kinases in vivo, occur at serines 20, 33 and 37 in response to IR and UV, in addition to serine-392 in response to UV. Phosphorylation of serine-15 and serine-20 displaces Mdm2 from p53, resulting in an increase in the half life of p53. Sequence-speci®c DNA binding of p53 is activated by acetylation of lysine residues 320, 373 and 382 by as yet unidenti®ed HATs in vivo particular interest in regard to the fact that, at least in some instances, p53 regulation in A-T cells following IR exposure is not totally abrogated but severely delayed. It is tempting to speculate, therefore, that ATR and ATM function in distinct, yet overlapping signalling pathways to p53 in response to dierent DNA damaging agents (see Figure 3) . Nevertheless, certain caveats should be introduced into the interpretation of some of these experiments. For example, over-expression of kinase dead mutants of ATR could interfere with other related signalling pathways, such as those mediated by ATM. Thus, although these experiments are highly informative, until an eective ATR null cell line has been established, the exact role of ATR in signalling DNA damage to p53 remains to be fully elucidated.
The Nijmegen breakage syndrome gene product NBS is a human autosomal recessive disorder that is relatively rare, with only approximately 70 aected families having been identi®ed world-wide. NBS is characterized by stunted growth, immune system defects and cancer pre-disposition. Similar to A-T, NBS cells are hypersensitive to IR and exhibit high degrees of chromosomal instability. Indeed, NBS cells were initially believed to be variants of A-T, due to these similarities in both clinical and cellular phenotypes (for review see Featherstone and Jackson, 1998) . Recently the NBS1 gene was cloned by conventional gene mapping techniques (Matsuura et al., 1998a; Varon et al., 1998) , and through a biochemical puri®cation that yielded the NBS1 gene product (Carney et al., 1998) . Primary sequence analysis of the NBS1 gene-product, a protein termed NBS1, p95 or Nibrin, revealed that it has no overall sequence similarities to previously identi®ed proteins. However, it does contain two domains that have been identi®ed in proteins involved in the detection and signalling of DNA damage, namely a forkhead-associated (FHA) domain, and a breast cancer carboxy-terminal (BRCT) domain (for review see Featherstone and Jackson, 1998) . A role of NBS1 in DNA repair has been indicated by the fact that NBS1 co-puri®es with and interacts with a complex containing the two mammalian proteins Mre11 and Rad50, which are functional homologues of the S. cerevisiae DNA double-strand break repair factors Mre11p and Rad50p (Ajimura et al., 1993) . However, the precise molecular mechanisms by which NBS1, Mre11 and Rad50 function in DNA repair remain to be elucidated.
The similarities between the clinical and cellular features of NBS and A-T has lead to speculation that the two corresponding gene products may function in similar ways in the detection and signalling of DNA damage. Furthermore, the observations that AT-NBS cell fusions are not fully complemented for radiationinduced chromosomal aberrations has promoted speculation that the products of these two genes may function in the same biochemical pathway (Stumm et al., 1997) . Indeed, similar to A-T cells, two independent studies have reported that induction of p53 in response to IR is defective in NBS cells, although defects in phosphorylation events in vivo were not assessed in these studies (Jongmans et al., 1997; Matsuura et al., 1998b) . Thus, in addition to ATM, it would appear that the product of the NBS1 gene is also involved in signalling to p53 in response to DNA damage. However, more recently, it has been reported that p53 regulation of NBS cells after exposure to IR is only partially defective, (Yamazaki et al., 1998) . Furthermore, these studies also revealed that p53-dependent G 1 arrest in response to IR was normal in NBS cells. Further studies are therefore required to establish the precise role of NBS1 in signalling to p53.
Summary and prospective
Work over the past few years has led to major insights into how p53 is activated in response to DNA damage. Particularly noteworthy has been progress in de®ning sites of p53 phosphorylation and acetylation, identifying which of these modi®cation events are induced after DNA damage, identifying the kinases, phosphatases and HATs that target p53, and de®ning how p53 levels and p53 activity are controlled by its association with other factors, such as Mdm2. One key goal for the future will be to determine in more detail how posttranslational modi®cation of p53 and p53-associated proteins leads to modulation of p53 activity in physiological contexts. It will also be of great interest to de®ne precisely how the kinases, phosphatases and HATs that function upstream of p53 in DNA damage signalling have their activity triggered by DNA damage. In this regard, it is tempting to speculate that, as DNA-PKcs activity is triggered upon association with DNA end-bound Ku, ATM and ATR will function in conjunction with other polypeptides that serve to target them to sites of DNA damage and thus activate their p53 kinase function under the appropriate physiological circumstances. Another important area will be to determine whether the dierent sites of p53 post-translational modi®cation function cooperatively or antagonistically in regulating p53-dependent DNA damage signalling events and, if they do, how this is accomplished. In addition, it will be of interest to study interfaces between DNA damage signalling and other signalling pathways that rely upon p53. Finally, it will be of great importance to establish the molecular basis for how p53-dependent DNA damage signalling can have markedly dierent outcomes in dierent cell types, or in the same cell type in dierent physiological settings. In addition to providing exciting insights into p53-dependent signalling processes, these studies are also likely to yield clues into how defects in p53 or its regulators contribute to cancer incidence in humans.
